BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30075986)

  • 1. Plasma contact factors as therapeutic targets.
    Tillman BF; Gruber A; McCarty OJT; Gailani D
    Blood Rev; 2018 Nov; 32(6):433-448. PubMed ID: 30075986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future prospects for contact factors as therapeutic targets.
    Gailani D
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):52-9. PubMed ID: 25696834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.
    Wheeler AP; Gailani D
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1099-114. PubMed ID: 27637310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting factor XI and factor XIa to prevent thrombosis.
    Gailani D; Gruber A
    Blood; 2024 Apr; 143(15):1465-1475. PubMed ID: 38142404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?
    van Montfoort ML; Meijers JC
    Thromb Haemost; 2013 Aug; 110(2):223-32. PubMed ID: 23739841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XI and XII as antithrombotic targets.
    Müller F; Gailani D; Renné T
    Curr Opin Hematol; 2011 Sep; 18(5):349-55. PubMed ID: 21730835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hemostatic role of factor XI.
    Puy C; Rigg RA; McCarty OJ
    Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S8-S11. PubMed ID: 27207433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic pathway of coagulation and arterial thrombosis.
    Gailani D; Renné T
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2507-13. PubMed ID: 17916770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rebirth of the contact pathway: a new therapeutic target.
    Srivastava P; Gailani D
    Curr Opin Hematol; 2020 Sep; 27(5):311-319. PubMed ID: 32740037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Safe Anticoagulation.
    Mailer RK; Kuta P; Renné T
    Hamostaseologie; 2022 Feb; 42(1):65-72. PubMed ID: 35196732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High molecular weight kininogen interactions with the homologs prekallikrein and factor XI: importance to surface-induced coagulation.
    Mohammed BM; Sun MF; Cheng Q; Litvak M; McCrae KR; Emsley J; McCarty OJT; Gailani D
    J Thromb Haemost; 2024 Jan; 22(1):225-237. PubMed ID: 37813198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel roles for factor XII-driven plasma contact activation system.
    Müller F; Renné T
    Curr Opin Hematol; 2008 Sep; 15(5):516-21. PubMed ID: 18695377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate.
    Alvarenga PH; Xu X; Oliveira F; Chagas AC; Nascimento CR; Francischetti IM; Juliano MA; Juliano L; Scharfstein J; Valenzuela JG; Ribeiro JM; Andersen JF
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2759-70. PubMed ID: 24092749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic Pathway of Coagulation and Thrombosis.
    Grover SP; Mackman N
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):331-338. PubMed ID: 30700128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic potential of the contact activation pathway.
    Schmaier AH
    Curr Opin Hematol; 2016 Sep; 23(5):445-52. PubMed ID: 27380557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor XI as a Therapeutic Target.
    Gailani D; Gruber A
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1316-22. PubMed ID: 27174099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.